Novo Nordisk's hemophilia A treatment approved by FDA

10/16/2013 | PharmaTimes (U.K.)

The FDA approved the use of Novo Nordisk's recombinant coagulation factor VIII drug Novoeight, or turoctocog alfa, to prevent and treat bleeding associated with hemophilia A. The firm plans to commercialize the drug shortly after the expiration of a third-party patent in April 2015.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
Nationwide, SL_Nationwide
Finance Manager - ENT
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA